 Tim Lahm
Concepts (468)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 56 | 2025 | 1910 | 9.560 |
Why?
| | Ventricular Dysfunction, Right | 22 | 2025 | 238 | 6.290 |
Why?
| | Ventricular Function, Right | 18 | 2025 | 285 | 3.780 |
Why?
| | Pulmonary Artery | 23 | 2023 | 1086 | 2.700 |
Why?
| | Hypoxia | 18 | 2024 | 1112 | 2.650 |
Why?
| | Estrogen Receptor alpha | 6 | 2024 | 145 | 2.400 |
Why?
| | Estradiol | 8 | 2021 | 521 | 2.230 |
Why?
| | Estrogens | 11 | 2023 | 367 | 1.930 |
Why?
| | Hypertrophy, Right Ventricular | 9 | 2023 | 145 | 1.600 |
Why?
| | Endothelial Cells | 9 | 2025 | 785 | 1.490 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 3 | 2021 | 51 | 1.460 |
Why?
| | Pulmonary Embolism | 4 | 2023 | 226 | 1.420 |
Why?
| | Estrogen Receptor beta | 3 | 2018 | 40 | 1.330 |
Why?
| | Rats, Sprague-Dawley | 30 | 2025 | 2486 | 1.320 |
Why?
| | Familial Primary Pulmonary Hypertension | 10 | 2023 | 198 | 1.290 |
Why?
| | Vasoconstriction | 8 | 2008 | 202 | 1.280 |
Why?
| | Sex Characteristics | 10 | 2022 | 762 | 1.220 |
Why?
| | Receptors, Estrogen | 4 | 2023 | 436 | 1.140 |
Why?
| | Lung | 13 | 2025 | 4060 | 1.110 |
Why?
| | Gonadal Steroid Hormones | 7 | 2021 | 140 | 1.100 |
Why?
| | Nitric Oxide | 5 | 2021 | 915 | 1.080 |
Why?
| | Rats | 29 | 2025 | 5647 | 1.030 |
Why?
| | Ventricular Function, Left | 5 | 2019 | 534 | 1.030 |
Why?
| | Animals | 67 | 2025 | 36940 | 1.000 |
Why?
| | Adaptation, Physiological | 4 | 2024 | 553 | 1.000 |
Why?
| | Lung Diseases | 5 | 2025 | 767 | 0.980 |
Why?
| | Apelin | 3 | 2021 | 10 | 0.970 |
Why?
| | Ventricular Remodeling | 6 | 2023 | 266 | 0.930 |
Why?
| | Heart Failure | 8 | 2023 | 2236 | 0.920 |
Why?
| | Heart | 5 | 2020 | 655 | 0.900 |
Why?
| | Disease Models, Animal | 19 | 2025 | 4295 | 0.790 |
Why?
| | Male | 62 | 2025 | 67762 | 0.750 |
Why?
| | Heart Ventricles | 9 | 2024 | 788 | 0.750 |
Why?
| | Humans | 83 | 2025 | 137585 | 0.740 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2018 | 278 | 0.730 |
Why?
| | Veterans | 6 | 2020 | 1476 | 0.700 |
Why?
| | Vascular Endothelial Growth Factor A | 11 | 2024 | 545 | 0.690 |
Why?
| | Ventricular Pressure | 7 | 2022 | 48 | 0.670 |
Why?
| | Stenosis, Pulmonary Artery | 1 | 2020 | 4 | 0.660 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2020 | 54 | 0.660 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2020 | 92 | 0.660 |
Why?
| | Renin-Angiotensin System | 1 | 2020 | 85 | 0.660 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 201 | 0.620 |
Why?
| | Iron | 2 | 2021 | 313 | 0.620 |
Why?
| | Sex Factors | 11 | 2025 | 2071 | 0.600 |
Why?
| | Vascular Remodeling | 6 | 2025 | 193 | 0.600 |
Why?
| | Cardiovascular System | 1 | 2020 | 137 | 0.600 |
Why?
| | Lung Injury | 2 | 2015 | 219 | 0.600 |
Why?
| | Telangiectasia, Hereditary Hemorrhagic | 1 | 2018 | 13 | 0.590 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2020 | 69 | 0.590 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2018 | 25 | 0.580 |
Why?
| | Histamine H2 Antagonists | 1 | 2018 | 30 | 0.570 |
Why?
| | Neovascularization, Pathologic | 2 | 2017 | 301 | 0.570 |
Why?
| | Liver Diseases | 1 | 2021 | 315 | 0.550 |
Why?
| | Oxygen Inhalation Therapy | 2 | 2017 | 157 | 0.550 |
Why?
| | Hyperoxia | 2 | 2015 | 90 | 0.550 |
Why?
| | Bronchodilator Agents | 2 | 2017 | 252 | 0.550 |
Why?
| | Vascular Diseases | 1 | 2020 | 243 | 0.540 |
Why?
| | Up-Regulation | 4 | 2021 | 843 | 0.540 |
Why?
| | Myocardial Contraction | 3 | 2017 | 341 | 0.530 |
Why?
| | Female | 47 | 2025 | 73304 | 0.520 |
Why?
| | High-Intensity Interval Training | 1 | 2016 | 25 | 0.520 |
Why?
| | Intention | 1 | 2018 | 170 | 0.510 |
Why?
| | Reperfusion Injury | 4 | 2011 | 279 | 0.470 |
Why?
| | Cell Hypoxia | 7 | 2018 | 226 | 0.460 |
Why?
| | Research | 1 | 2018 | 451 | 0.460 |
Why?
| | Hemodynamics | 7 | 2022 | 1113 | 0.410 |
Why?
| | Physical Conditioning, Animal | 3 | 2025 | 257 | 0.400 |
Why?
| | Blood Pressure | 4 | 2015 | 1786 | 0.390 |
Why?
| | Hypertension | 2 | 2021 | 1295 | 0.370 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2012 | 46 | 0.370 |
Why?
| | Whipple Disease | 1 | 2011 | 6 | 0.370 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 19 | 0.360 |
Why?
| | Embolism, Air | 1 | 2011 | 14 | 0.360 |
Why?
| | Magnesium Sulfate | 1 | 2011 | 17 | 0.360 |
Why?
| | Pneumothorax | 1 | 2011 | 38 | 0.360 |
Why?
| | Signal Transduction | 9 | 2020 | 5079 | 0.350 |
Why?
| | Leukapheresis | 1 | 2010 | 21 | 0.340 |
Why?
| | Pulmonary Medicine | 2 | 2024 | 85 | 0.340 |
Why?
| | Bradykinin | 1 | 2010 | 46 | 0.330 |
Why?
| | Calcium Channel Blockers | 1 | 2011 | 167 | 0.330 |
Why?
| | Pulmonary Circulation | 3 | 2023 | 429 | 0.330 |
Why?
| | Sepsis | 3 | 2010 | 617 | 0.310 |
Why?
| | Paracrine Communication | 6 | 2008 | 65 | 0.310 |
Why?
| | Leukocytes | 1 | 2010 | 311 | 0.300 |
Why?
| | Myocardium | 5 | 2020 | 1002 | 0.300 |
Why?
| | Aged | 14 | 2021 | 23961 | 0.290 |
Why?
| | Calcium | 2 | 2012 | 1199 | 0.290 |
Why?
| | Blastomycosis | 1 | 2008 | 10 | 0.290 |
Why?
| | Acute Lung Injury | 1 | 2011 | 287 | 0.290 |
Why?
| | Altitude | 2 | 2024 | 488 | 0.280 |
Why?
| | Fellowships and Scholarships | 2 | 2024 | 306 | 0.280 |
Why?
| | Biomedical Research | 2 | 2025 | 692 | 0.270 |
Why?
| | Stroke Volume | 3 | 2020 | 612 | 0.270 |
Why?
| | Endothelins | 1 | 2007 | 65 | 0.260 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2007 | 86 | 0.260 |
Why?
| | Middle Aged | 15 | 2021 | 33479 | 0.260 |
Why?
| | Cardiotonic Agents | 2 | 2021 | 124 | 0.260 |
Why?
| | Menstrual Cycle | 1 | 2007 | 133 | 0.250 |
Why?
| | Vascular Resistance | 2 | 2020 | 375 | 0.250 |
Why?
| | Adult | 15 | 2024 | 37929 | 0.250 |
Why?
| | Administration, Inhalation | 2 | 2019 | 688 | 0.250 |
Why?
| | Monocrotaline | 3 | 2022 | 28 | 0.240 |
Why?
| | Fruit and Vegetable Juices | 1 | 2025 | 15 | 0.240 |
Why?
| | Calcium Signaling | 1 | 2007 | 249 | 0.230 |
Why?
| | Nitrates | 1 | 2025 | 92 | 0.230 |
Why?
| | Neoplasms | 1 | 2020 | 2671 | 0.230 |
Why?
| | Rats, Mutant Strains | 2 | 2021 | 25 | 0.220 |
Why?
| | Propionates | 2 | 2018 | 39 | 0.220 |
Why?
| | United States | 13 | 2025 | 14841 | 0.220 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 565 | 0.220 |
Why?
| | Myocardial Reperfusion Injury | 3 | 2010 | 135 | 0.220 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2007 | 455 | 0.220 |
Why?
| | Antihypertensive Agents | 2 | 2018 | 494 | 0.210 |
Why?
| | Reproductive Health Services | 1 | 2023 | 19 | 0.210 |
Why?
| | Databases, Factual | 2 | 2020 | 1357 | 0.210 |
Why?
| | Autophagy | 2 | 2016 | 284 | 0.210 |
Why?
| | Nitriles | 2 | 2018 | 172 | 0.210 |
Why?
| | SOXF Transcription Factors | 2 | 2023 | 16 | 0.200 |
Why?
| | Myocytes, Cardiac | 3 | 2021 | 526 | 0.200 |
Why?
| | Double-Blind Method | 2 | 2019 | 1993 | 0.200 |
Why?
| | Chloride Channels | 1 | 2023 | 35 | 0.200 |
Why?
| | Echocardiography | 2 | 2017 | 642 | 0.200 |
Why?
| | Stem Cell Transplantation | 3 | 2008 | 176 | 0.200 |
Why?
| | Aged, 80 and over | 7 | 2021 | 7635 | 0.190 |
Why?
| | United States Department of Veterans Affairs | 2 | 2017 | 678 | 0.190 |
Why?
| | Chlorides | 1 | 2023 | 136 | 0.190 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2526 | 0.190 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 313 | 0.190 |
Why?
| | Intercellular Signaling Peptides and Proteins | 3 | 2015 | 382 | 0.180 |
Why?
| | Dehydroepiandrosterone Sulfate | 1 | 2021 | 46 | 0.180 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2022 | 151 | 0.180 |
Why?
| | Societies, Medical | 3 | 2025 | 820 | 0.180 |
Why?
| | Mice | 13 | 2023 | 17787 | 0.180 |
Why?
| | Menopause, Premature | 1 | 2021 | 12 | 0.180 |
Why?
| | Atrial Pressure | 1 | 2020 | 3 | 0.170 |
Why?
| | Metabolic Diseases | 1 | 2021 | 108 | 0.170 |
Why?
| | Phenylephrine | 3 | 2008 | 75 | 0.170 |
Why?
| | Cytokines | 5 | 2015 | 2085 | 0.170 |
Why?
| | Receptors, Androgen | 1 | 2021 | 150 | 0.170 |
Why?
| | Vasodilator Agents | 2 | 2013 | 331 | 0.160 |
Why?
| | Hormones | 1 | 2021 | 143 | 0.160 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 486 | 0.160 |
Why?
| | Testosterone | 4 | 2014 | 409 | 0.160 |
Why?
| | Body Weight | 2 | 2015 | 985 | 0.160 |
Why?
| | Inflammation | 3 | 2024 | 2837 | 0.160 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1587 | 0.160 |
Why?
| | Models, Cardiovascular | 1 | 2021 | 198 | 0.160 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 4 | 2022 | 104 | 0.160 |
Why?
| | Drugs, Investigational | 1 | 2019 | 33 | 0.160 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 220 | 0.160 |
Why?
| | Ovariectomy | 4 | 2015 | 152 | 0.160 |
Why?
| | Young Adult | 8 | 2021 | 13209 | 0.160 |
Why?
| | Organ Size | 1 | 2020 | 477 | 0.160 |
Why?
| | Vasoconstrictor Agents | 3 | 2008 | 139 | 0.160 |
Why?
| | Mesenchymal Stem Cell Transplantation | 3 | 2008 | 52 | 0.160 |
Why?
| | Cardiac Catheterization | 2 | 2020 | 530 | 0.160 |
Why?
| | Mice, Knockout | 4 | 2021 | 3015 | 0.160 |
Why?
| | Muscle, Skeletal | 3 | 2025 | 1724 | 0.150 |
Why?
| | HLA-DP alpha-Chains | 1 | 2018 | 4 | 0.150 |
Why?
| | Y Chromosome | 1 | 2018 | 11 | 0.150 |
Why?
| | Gender Identity | 1 | 2019 | 124 | 0.150 |
Why?
| | Propensity Score | 1 | 2020 | 294 | 0.150 |
Why?
| | Animals, Newborn | 4 | 2015 | 844 | 0.150 |
Why?
| | Lipopolysaccharides | 4 | 2010 | 886 | 0.150 |
Why?
| | Troponin T | 1 | 2019 | 65 | 0.150 |
Why?
| | RNA, Long Noncoding | 1 | 2021 | 181 | 0.150 |
Why?
| | Respiratory Mucosa | 1 | 2021 | 321 | 0.150 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2018 | 22 | 0.150 |
Why?
| | Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2018 | 21 | 0.150 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2016 | 204 | 0.150 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.150 |
Why?
| | HLA-DP beta-Chains | 1 | 2018 | 86 | 0.150 |
Why?
| | Arterial Pressure | 2 | 2016 | 126 | 0.150 |
Why?
| | Metabolome | 1 | 2021 | 350 | 0.140 |
Why?
| | Adult Stem Cells | 2 | 2008 | 40 | 0.140 |
Why?
| | RNA, Messenger | 4 | 2021 | 2833 | 0.140 |
Why?
| | Oxygen Consumption | 2 | 2024 | 696 | 0.140 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2017 | 283 | 0.140 |
Why?
| | Isolated Heart Preparation | 1 | 2017 | 6 | 0.140 |
Why?
| | Bronchoscopy | 3 | 2021 | 223 | 0.140 |
Why?
| | Protein Stability | 1 | 2018 | 176 | 0.140 |
Why?
| | bcl-2-Associated X Protein | 1 | 2017 | 56 | 0.140 |
Why?
| | Risk Assessment | 4 | 2023 | 3457 | 0.140 |
Why?
| | Cardiac Output | 3 | 2015 | 165 | 0.140 |
Why?
| | Cells, Cultured | 6 | 2018 | 4193 | 0.140 |
Why?
| | Diastole | 1 | 2017 | 149 | 0.140 |
Why?
| | Peptide Fragments | 2 | 2019 | 706 | 0.130 |
Why?
| | CD55 Antigens | 1 | 2016 | 30 | 0.130 |
Why?
| | Myocardial Infarction | 2 | 2019 | 1046 | 0.130 |
Why?
| | Dietary Supplements | 1 | 2021 | 561 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 233 | 0.130 |
Why?
| | Pyrroles | 1 | 2017 | 213 | 0.130 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 243 | 0.130 |
Why?
| | Computed Tomography Angiography | 1 | 2017 | 129 | 0.130 |
Why?
| | Personnel Selection | 1 | 2017 | 78 | 0.120 |
Why?
| | Metabolic Syndrome | 1 | 2020 | 354 | 0.120 |
Why?
| | Epithelium | 1 | 2016 | 313 | 0.120 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2019 | 382 | 0.120 |
Why?
| | Health Services Accessibility | 1 | 2023 | 986 | 0.120 |
Why?
| | Women's Health | 1 | 2018 | 372 | 0.120 |
Why?
| | Dyspnea | 1 | 2017 | 254 | 0.120 |
Why?
| | Research Report | 1 | 2016 | 83 | 0.120 |
Why?
| | Biological Assay | 1 | 2016 | 124 | 0.120 |
Why?
| | Golgi Apparatus | 1 | 2015 | 100 | 0.120 |
Why?
| | Melanocytes | 1 | 2015 | 65 | 0.120 |
Why?
| | Genetic Testing | 1 | 2018 | 460 | 0.120 |
Why?
| | Telemetry | 1 | 2015 | 40 | 0.120 |
Why?
| | Stem Cells | 3 | 2008 | 594 | 0.120 |
Why?
| | Physical Exertion | 1 | 2016 | 215 | 0.120 |
Why?
| | Physical Endurance | 1 | 2016 | 275 | 0.120 |
Why?
| | Sleep Wake Disorders | 1 | 2018 | 286 | 0.110 |
Why?
| | Pulmonary Blastoma | 1 | 2014 | 8 | 0.110 |
Why?
| | Macrophages | 1 | 2022 | 1547 | 0.110 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2015 | 85 | 0.110 |
Why?
| | Models, Biological | 6 | 2021 | 1783 | 0.110 |
Why?
| | Indoles | 1 | 2017 | 412 | 0.110 |
Why?
| | Familial Hypophosphatemic Rickets | 1 | 2014 | 6 | 0.110 |
Why?
| | Health Policy | 1 | 2017 | 388 | 0.110 |
Why?
| | Chest Pain | 1 | 2014 | 91 | 0.110 |
Why?
| | Dehydroepiandrosterone | 1 | 2014 | 51 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2016 | 10811 | 0.110 |
Why?
| | Transcriptome | 1 | 2020 | 971 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1236 | 0.110 |
Why?
| | Apoptosis | 2 | 2015 | 2553 | 0.100 |
Why?
| | Splenectomy | 1 | 2013 | 62 | 0.100 |
Why?
| | World Health Organization | 1 | 2013 | 123 | 0.100 |
Why?
| | Ovary | 1 | 2015 | 221 | 0.100 |
Why?
| | Oxygen | 2 | 2015 | 931 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 429 | 0.100 |
Why?
| | Fever | 1 | 2014 | 306 | 0.100 |
Why?
| | Phosphates | 1 | 2014 | 182 | 0.100 |
Why?
| | Pulmonary Alveoli | 1 | 2015 | 405 | 0.100 |
Why?
| | Diagnosis, Differential | 2 | 2014 | 1483 | 0.100 |
Why?
| | Pulmonary Veins | 1 | 2014 | 99 | 0.100 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2015 | 249 | 0.100 |
Why?
| | Fibroblast Growth Factors | 1 | 2014 | 172 | 0.100 |
Why?
| | Ischemia | 3 | 2015 | 409 | 0.100 |
Why?
| | Myocardial Ischemia | 3 | 2008 | 263 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2011 | 2057 | 0.100 |
Why?
| | Exercise | 1 | 2024 | 2057 | 0.090 |
Why?
| | ROC Curve | 1 | 2014 | 554 | 0.090 |
Why?
| | Estrogen Antagonists | 1 | 2012 | 45 | 0.090 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 75 | 0.090 |
Why?
| | Mutation, Missense | 1 | 2014 | 341 | 0.090 |
Why?
| | Myocardial Perfusion Imaging | 1 | 2011 | 40 | 0.090 |
Why?
| | Length of Stay | 1 | 2017 | 1215 | 0.090 |
Why?
| | Airway Remodeling | 1 | 2012 | 64 | 0.090 |
Why?
| | Heart Arrest | 1 | 2015 | 339 | 0.090 |
Why?
| | Models, Animal | 2 | 2010 | 384 | 0.090 |
Why?
| | Mice, Inbred C57BL | 8 | 2019 | 5757 | 0.090 |
Why?
| | Oxidoreductases | 1 | 2011 | 92 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2017 | 654 | 0.090 |
Why?
| | Ceramides | 1 | 2011 | 118 | 0.090 |
Why?
| | Endothelium, Vascular | 2 | 2007 | 927 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2017 | 15657 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2008 | 1242 | 0.090 |
Why?
| | Exercise Therapy | 1 | 2015 | 443 | 0.090 |
Why?
| | Asthma | 2 | 2021 | 2295 | 0.080 |
Why?
| | Exercise Test | 2 | 2024 | 625 | 0.080 |
Why?
| | Acute Disease | 2 | 2010 | 1007 | 0.080 |
Why?
| | Immunomodulation | 1 | 2010 | 98 | 0.080 |
Why?
| | Angiopoietin-1 | 1 | 2009 | 11 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2015 | 1396 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2111 | 0.080 |
Why?
| | Propofol | 1 | 2009 | 73 | 0.080 |
Why?
| | Immune System | 1 | 2010 | 177 | 0.080 |
Why?
| | Radiography | 1 | 2011 | 822 | 0.080 |
Why?
| | Prognosis | 1 | 2017 | 4030 | 0.080 |
Why?
| | Rabbits | 1 | 2010 | 794 | 0.070 |
Why?
| | Coronary Artery Bypass | 1 | 2010 | 234 | 0.070 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2008 | 48 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 43 | 0.070 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2008 | 28 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 87 | 0.070 |
Why?
| | Vasodilation | 1 | 2011 | 499 | 0.070 |
Why?
| | Colorado | 1 | 2018 | 4565 | 0.070 |
Why?
| | Positive-Pressure Respiration | 1 | 2008 | 80 | 0.070 |
Why?
| | Phenols | 1 | 2008 | 99 | 0.070 |
Why?
| | Ventricular Function | 1 | 2007 | 61 | 0.070 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 162 | 0.070 |
Why?
| | Hypnotics and Sedatives | 1 | 2009 | 200 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 815 | 0.070 |
Why?
| | Pluripotent Stem Cells | 1 | 2008 | 80 | 0.070 |
Why?
| | Pyruvates | 1 | 2007 | 24 | 0.070 |
Why?
| | Antifungal Agents | 1 | 2008 | 136 | 0.070 |
Why?
| | Embryonic Stem Cells | 1 | 2008 | 129 | 0.070 |
Why?
| | Education | 2 | 2018 | 108 | 0.070 |
Why?
| | Steroids | 1 | 2008 | 167 | 0.070 |
Why?
| | Dihydrotestosterone | 1 | 2007 | 44 | 0.070 |
Why?
| | Deferoxamine | 1 | 2007 | 24 | 0.070 |
Why?
| | Iron Chelating Agents | 1 | 2007 | 18 | 0.070 |
Why?
| | Fibrosis | 2 | 2020 | 552 | 0.070 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2007 | 50 | 0.070 |
Why?
| | Nurses | 1 | 2009 | 180 | 0.070 |
Why?
| | Anesthesia | 1 | 2009 | 189 | 0.070 |
Why?
| | Bone Marrow Transplantation | 1 | 2008 | 286 | 0.070 |
Why?
| | Internship and Residency | 1 | 2017 | 1147 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2009 | 323 | 0.060 |
Why?
| | Homeostasis | 1 | 2010 | 621 | 0.060 |
Why?
| | rho-Associated Kinases | 1 | 2007 | 83 | 0.060 |
Why?
| | Carbon Dioxide | 1 | 2008 | 267 | 0.060 |
Why?
| | Amino Acids, Dicarboxylic | 2 | 2016 | 8 | 0.060 |
Why?
| | Emphysema | 1 | 2007 | 106 | 0.060 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 209 | 0.060 |
Why?
| | Epithelial Cells | 2 | 2016 | 1096 | 0.060 |
Why?
| | Interleukin-6 | 2 | 2008 | 778 | 0.060 |
Why?
| | Hospitalization | 1 | 2016 | 2199 | 0.060 |
Why?
| | Androgens | 1 | 2007 | 187 | 0.060 |
Why?
| | Coronary Disease | 1 | 2008 | 385 | 0.060 |
Why?
| | Endothelin-1 | 1 | 2007 | 182 | 0.060 |
Why?
| | Beta vulgaris | 1 | 2025 | 12 | 0.060 |
Why?
| | Gene Expression | 2 | 2021 | 1502 | 0.060 |
Why?
| | Research Design | 2 | 2025 | 1139 | 0.060 |
Why?
| | Inflammation Mediators | 1 | 2008 | 513 | 0.060 |
Why?
| | Cyclic GMP | 1 | 2025 | 93 | 0.060 |
Why?
| | Prospective Studies | 1 | 2017 | 7604 | 0.060 |
Why?
| | Body Mass Index | 1 | 2014 | 2389 | 0.060 |
Why?
| | Pyrazoles | 1 | 2008 | 423 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 840 | 0.060 |
Why?
| | MAP Kinase Signaling System | 1 | 2007 | 320 | 0.060 |
Why?
| | Risk Factors | 2 | 2021 | 10388 | 0.060 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2007 | 446 | 0.060 |
Why?
| | Embolectomy | 1 | 2023 | 13 | 0.050 |
Why?
| | NF-kappa B | 1 | 2008 | 691 | 0.050 |
Why?
| | Orchiectomy | 3 | 2008 | 71 | 0.050 |
Why?
| | Anti-Inflammatory Agents | 1 | 2007 | 496 | 0.050 |
Why?
| | Regional Blood Flow | 1 | 2025 | 474 | 0.050 |
Why?
| | Genetic Variation | 2 | 2018 | 991 | 0.050 |
Why?
| | HMGB Proteins | 1 | 2023 | 18 | 0.050 |
Why?
| | Thrombolytic Therapy | 1 | 2023 | 142 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 85 | 0.050 |
Why?
| | Thorax | 1 | 2022 | 50 | 0.050 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2007 | 383 | 0.050 |
Why?
| | Mechanotransduction, Cellular | 1 | 2023 | 111 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2017 | 6079 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 623 | 0.040 |
Why?
| | Breath Tests | 1 | 2021 | 87 | 0.040 |
Why?
| | Aging | 2 | 2008 | 1864 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2021 | 173 | 0.040 |
Why?
| | Fibrillar Collagens | 1 | 2020 | 13 | 0.040 |
Why?
| | Kallikreins | 1 | 2020 | 29 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2020 | 55 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2022 | 455 | 0.040 |
Why?
| | Incidental Findings | 1 | 2021 | 87 | 0.040 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2020 | 40 | 0.040 |
Why?
| | Vital Capacity | 1 | 2021 | 311 | 0.040 |
Why?
| | Cattle | 1 | 2023 | 984 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2015 | 810 | 0.040 |
Why?
| | Biological Specimen Banks | 1 | 2021 | 102 | 0.040 |
Why?
| | Down-Regulation | 2 | 2016 | 657 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 318 | 0.040 |
Why?
| | Mitochondria, Heart | 1 | 2020 | 102 | 0.040 |
Why?
| | Kinetics | 2 | 2015 | 1670 | 0.040 |
Why?
| | Forced Expiratory Volume | 1 | 2021 | 531 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 664 | 0.040 |
Why?
| | NAD | 1 | 2020 | 77 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2018 | 75 | 0.040 |
Why?
| | Critical Care | 1 | 2023 | 601 | 0.040 |
Why?
| | Cell Shape | 2 | 2008 | 57 | 0.040 |
Why?
| | Behavior | 1 | 2018 | 90 | 0.040 |
Why?
| | Cohort Studies | 2 | 2021 | 5742 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2023 | 827 | 0.040 |
Why?
| | Curriculum | 1 | 2024 | 992 | 0.040 |
Why?
| | Hepatocyte Growth Factor | 2 | 2008 | 35 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 128 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2007 | 2607 | 0.040 |
Why?
| | Sleep Apnea Syndromes | 1 | 2018 | 88 | 0.030 |
Why?
| | RNA, Small Interfering | 2 | 2011 | 622 | 0.030 |
Why?
| | Job Application | 1 | 2017 | 17 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1118 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2018 | 233 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 171 | 0.030 |
Why?
| | Comprehension | 1 | 2018 | 172 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2020 | 810 | 0.030 |
Why?
| | Proteomics | 1 | 2023 | 1111 | 0.030 |
Why?
| | Prolyl Hydroxylases | 1 | 2015 | 4 | 0.030 |
Why?
| | Adolescent | 4 | 2021 | 21513 | 0.030 |
Why?
| | Prolyl-Hydroxylase Inhibitors | 1 | 2015 | 5 | 0.030 |
Why?
| | Gene Silencing | 1 | 2016 | 195 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2008 | 319 | 0.030 |
Why?
| | Blood Urea Nitrogen | 1 | 2015 | 54 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2015 | 3412 | 0.030 |
Why?
| | Cyclopentanes | 1 | 2015 | 19 | 0.030 |
Why?
| | Pulmonary Gas Exchange | 1 | 2015 | 121 | 0.030 |
Why?
| | Renal Circulation | 1 | 2015 | 58 | 0.030 |
Why?
| | Chloroquine | 1 | 2015 | 54 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1325 | 0.030 |
Why?
| | Lysosomes | 1 | 2015 | 141 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 852 | 0.030 |
Why?
| | Age Factors | 2 | 2015 | 3295 | 0.030 |
Why?
| | Proteolysis | 1 | 2015 | 177 | 0.030 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2015 | 156 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 628 | 0.030 |
Why?
| | Steroid Hydroxylases | 1 | 2014 | 22 | 0.030 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2014 | 15 | 0.030 |
Why?
| | Protein Folding | 1 | 2015 | 280 | 0.030 |
Why?
| | Gene Knock-In Techniques | 1 | 2014 | 56 | 0.030 |
Why?
| | Protein Transport | 1 | 2015 | 445 | 0.030 |
Why?
| | Calcitriol | 1 | 2014 | 58 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 167 | 0.030 |
Why?
| | Creatinine | 1 | 2015 | 499 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2014 | 298 | 0.030 |
Why?
| | Complement Activation | 1 | 2016 | 415 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 362 | 0.030 |
Why?
| | Glycolysis | 1 | 2015 | 321 | 0.030 |
Why?
| | Endoplasmic Reticulum | 1 | 2015 | 265 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 307 | 0.020 |
Why?
| | Phosphorylation | 2 | 2008 | 1759 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2015 | 620 | 0.020 |
Why?
| | Pyrimidines | 1 | 2015 | 470 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 1431 | 0.020 |
Why?
| | Computer Simulation | 1 | 2016 | 978 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 2 | 2008 | 916 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 2189 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 1040 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2828 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2426 | 0.020 |
Why?
| | Biosensing Techniques | 1 | 2011 | 129 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2031 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3196 | 0.020 |
Why?
| | Infant | 2 | 2017 | 9465 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 2892 | 0.020 |
Why?
| | Mutation | 1 | 2020 | 3958 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1457 | 0.020 |
Why?
| | Child, Preschool | 2 | 2017 | 11074 | 0.020 |
Why?
| | Short Bowel Syndrome | 1 | 2008 | 26 | 0.020 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2008 | 38 | 0.020 |
Why?
| | Propanolamines | 1 | 2009 | 96 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2011 | 739 | 0.020 |
Why?
| | Endotoxins | 1 | 2009 | 220 | 0.020 |
Why?
| | Organ Specificity | 1 | 2008 | 305 | 0.020 |
Why?
| | Stromal Cells | 1 | 2008 | 112 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2009 | 179 | 0.020 |
Why?
| | Tissue and Organ Harvesting | 1 | 2008 | 70 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2008 | 87 | 0.020 |
Why?
| | Osteoblasts | 1 | 2008 | 126 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2007 | 110 | 0.020 |
Why?
| | Organ Culture Techniques | 1 | 2007 | 156 | 0.020 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2007 | 29 | 0.020 |
Why?
| | Cell Lineage | 1 | 2008 | 350 | 0.020 |
Why?
| | RNA Interference | 1 | 2008 | 469 | 0.020 |
Why?
| | Tibia | 1 | 2008 | 178 | 0.020 |
Why?
| | Adipocytes | 1 | 2008 | 222 | 0.020 |
Why?
| | Administration, Oral | 1 | 2009 | 816 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2008 | 1092 | 0.020 |
Why?
| | Transfection | 1 | 2008 | 945 | 0.020 |
Why?
| | Femur | 1 | 2008 | 254 | 0.020 |
Why?
| | Diet | 1 | 2014 | 1278 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2009 | 956 | 0.020 |
Why?
| | Thoracic Surgery | 1 | 2007 | 132 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2008 | 1316 | 0.010 |
Why?
| | Tissue Engineering | 1 | 2008 | 423 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2691 | 0.010 |
Why?
| | Heart Diseases | 1 | 2007 | 346 | 0.010 |
Why?
| | Blotting, Western | 1 | 2007 | 1226 | 0.010 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2008 | 351 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2011 | 2475 | 0.010 |
Why?
| | Child | 2 | 2017 | 21935 | 0.010 |
Why?
| | Glucose | 1 | 2009 | 1020 | 0.010 |
Why?
| | Interleukin-1 | 1 | 2007 | 965 | 0.010 |
Why?
| | Fibroblasts | 1 | 2008 | 996 | 0.010 |
Why?
| | Fetus | 1 | 2007 | 806 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2847 | 0.010 |
Why?
| | Pregnancy | 1 | 2014 | 6763 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2008 | 1991 | 0.010 |
Why?
| | Neurons | 1 | 2008 | 1590 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 6828 | 0.010 |
Why?
|
|
Lahm's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|